Morgan Stanley Leap Therapeutics, Inc. Transaction History

Morgan Stanley

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$0.29 - $0.72 $120 - $298	414 Added 4.17%	10,334 $3,000
Q4 2022 Feb 14, 2023	SELL	$0.42 - $9.18 $28,856 - $630,730	-68,707 Reduced 87.38%	9,920 $4,000
Q3 2022 Nov 14, 2022	BUY	$0.92 - $9.3 $1,070 - $10,825	1,164 Added 1.5%	78,627 $70,000
Q2 2022 Oct 27, 2022	SELL	$0.96 - $1.91 $597,015 - $1.19 Million	-621,891 Reduced 88.92%	77,463 $89,000
Q2 2022 Aug 15, 2022	SELL	$0.96 - $1.91 $597,015 - $1.19 Million	-621,891 Reduced 88.92%	77,463 $89,000
Q1 2022 Oct 27, 2022	BUY	$1.6 - $3.35 $995,025 - $2.08 Million	621,891 Added 802.82%	699,354 $1.22 Million
Q1 2022 May 13, 2022	BUY	$1.6 - $3.35 $638,912 - $1.34 Million	399,320 Added 133.09%	699,354 $1.22 Million
Q4 2021 Feb 14, 2022	BUY	$2.08 - $3.65 $370,830 - $650,736	178,284 Added 146.43%	300,034 $972,000
Q3 2021 Nov 15, 2021	BUY	$1.35 - $4.01 $164,362 - $488,217	121,750 New	121,750 $489,000

265K

Ticker LPTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,021,400
Market Cap $275M
Description
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate can...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.